JP2020517658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517658A5 JP2020517658A5 JP2019557434A JP2019557434A JP2020517658A5 JP 2020517658 A5 JP2020517658 A5 JP 2020517658A5 JP 2019557434 A JP2019557434 A JP 2019557434A JP 2019557434 A JP2019557434 A JP 2019557434A JP 2020517658 A5 JP2020517658 A5 JP 2020517658A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- antibody
- cancer
- ecm
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 96
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 40
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 21
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 21
- 210000002744 extracellular matrix Anatomy 0.000 claims description 21
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 16
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 16
- 102100036537 von Willebrand factor Human genes 0.000 claims description 16
- 229960001134 von willebrand factor Drugs 0.000 claims description 16
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 13
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 9
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102000004237 Decorin Human genes 0.000 claims description 4
- 108090000738 Decorin Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 3
- 102100035194 Placenta growth factor Human genes 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000002601 intratumoral effect Effects 0.000 claims description 3
- WKHJQIQDQXGUOD-UHFFFAOYSA-N 4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydrobenzo[g]chromene-5,10-dione Chemical compound OC1C(C)(C)OC(C(C2=CC=CC=C2C2=O)=O)=C2C1NCC1=CC=CC=C1 WKHJQIQDQXGUOD-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 229940123189 CD40 agonist Drugs 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 102000002698 KIR Receptors Human genes 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims description 2
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000012191 childhood neoplasm Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 210000002308 embryonic cell Anatomy 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000001571 immunoadjuvant effect Effects 0.000 claims description 2
- 239000000568 immunological adjuvant Substances 0.000 claims description 2
- 229950009034 indoximod Drugs 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- -1 norhalman Chemical compound 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 206010044285 tracheal cancer Diseases 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 4
- 238000011275 oncology therapy Methods 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 241000283080 Proboscidea <mammal> Species 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 229940077095 MUC-1 inhibitor Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024001630A JP2024041874A (ja) | 2017-04-20 | 2024-01-10 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487823P | 2017-04-20 | 2017-04-20 | |
| US62/487,823 | 2017-04-20 | ||
| PCT/US2018/028505 WO2018195386A1 (en) | 2017-04-20 | 2018-04-20 | Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001630A Division JP2024041874A (ja) | 2017-04-20 | 2024-01-10 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517658A JP2020517658A (ja) | 2020-06-18 |
| JP2020517658A5 true JP2020517658A5 (OSRAM) | 2021-05-27 |
| JP7419070B2 JP7419070B2 (ja) | 2024-01-22 |
Family
ID=63856403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557434A Active JP7419070B2 (ja) | 2017-04-20 | 2018-04-20 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
| JP2024001630A Pending JP2024041874A (ja) | 2017-04-20 | 2024-01-10 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001630A Pending JP2024041874A (ja) | 2017-04-20 | 2024-01-10 | 免疫療法用抗体と連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11574747B2 (OSRAM) |
| EP (1) | EP3612209A4 (OSRAM) |
| JP (2) | JP7419070B2 (OSRAM) |
| CN (1) | CN111132693A (OSRAM) |
| AU (2) | AU2018256453B2 (OSRAM) |
| MX (1) | MX2019012579A (OSRAM) |
| WO (1) | WO2018195386A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2889182A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| CN108623686A (zh) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| AU2018256453B2 (en) * | 2017-04-20 | 2024-02-08 | The University Of Chicago | Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies |
| WO2019094938A2 (en) | 2017-11-13 | 2019-05-16 | The University Of Chicago | Methods and compositions for the treatment of wounds |
| BR112020018196A2 (pt) | 2018-03-05 | 2020-12-29 | The University Of Chicago | Métodos e composições para tratar câncer com peptídeos de afinidade com ecm ligados a citocinas |
| WO2020009938A1 (en) | 2018-07-03 | 2020-01-09 | Catalent Pharma Solutions, Llc | Multifunctional protein molecules comprising decorin and use thereof |
| EP3930687A4 (en) * | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| CN114206355A (zh) * | 2019-06-03 | 2022-03-18 | 芝加哥大学 | 用靶向癌症的佐剂治疗癌症的方法和组合物 |
| CN115135386A (zh) * | 2019-12-19 | 2022-09-30 | 得克萨斯州大学系统董事会 | 用于治疗胶质母细胞瘤的方法 |
| CN115065734A (zh) * | 2021-02-27 | 2022-09-16 | 华为技术有限公司 | 一种数据处理方法、装置及芯片 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654270A (en) * | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
| AU6934600A (en) | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
| KR20030060772A (ko) * | 2000-05-05 | 2003-07-16 | 지티씨바이오쎄라퓨틱스,인크. | 형질전환법으로 생성된 데코린 |
| US20080160024A1 (en) * | 2006-12-07 | 2008-07-03 | Board Of Trustees Of The University Of Arkansas | Inhibition of cancer metastasis |
| AT504685B1 (de) * | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
| RU2579977C2 (ru) * | 2009-11-13 | 2016-04-10 | Грифольс Терапьютикс Инк. | СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ |
| US9879062B2 (en) * | 2012-07-03 | 2018-01-30 | Ecole Polytechnique Federale De Lausanne | Protein-binding peptide isolated from placenta growth factor |
| US10420820B2 (en) * | 2014-09-29 | 2019-09-24 | Counterpoint Biomedia LLC | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| CN111375066B (zh) | 2015-07-16 | 2023-04-25 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| AU2018256453B2 (en) * | 2017-04-20 | 2024-02-08 | The University Of Chicago | Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies |
-
2018
- 2018-04-20 AU AU2018256453A patent/AU2018256453B2/en active Active
- 2018-04-20 US US16/606,539 patent/US11574747B2/en active Active
- 2018-04-20 WO PCT/US2018/028505 patent/WO2018195386A1/en not_active Ceased
- 2018-04-20 JP JP2019557434A patent/JP7419070B2/ja active Active
- 2018-04-20 EP EP18787963.0A patent/EP3612209A4/en active Pending
- 2018-04-20 MX MX2019012579A patent/MX2019012579A/es unknown
- 2018-04-20 CN CN201880041832.4A patent/CN111132693A/zh active Pending
-
2023
- 2023-02-03 US US18/164,164 patent/US20230377764A1/en active Pending
-
2024
- 2024-01-10 JP JP2024001630A patent/JP2024041874A/ja active Pending
- 2024-05-02 AU AU2024202918A patent/AU2024202918A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517658A5 (OSRAM) | ||
| Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
| Balza et al. | Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin | |
| Fallon et al. | The immunocytokine NHS-IL12 as a potential cancer therapeutic | |
| JP6858558B2 (ja) | 新生物疾患の処置、減少、阻害、又は制御において使用するための、免疫調節薬 | |
| JP2023524530A (ja) | 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法 | |
| JP2021020909A (ja) | がんの治療のための方法、組成物、及びキット | |
| EP3328363A1 (en) | Compositions and methods for immunomodulation | |
| JP2016527286A5 (OSRAM) | ||
| JP2019526578A (ja) | キャリアー−ｐｄ−ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 | |
| JP2021120418A (ja) | がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム | |
| US20220008515A1 (en) | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor | |
| JP7139293B2 (ja) | Ｇｄ２陽性がんを処置するための製剤および方法 | |
| CN103536917B (zh) | 干扰素在治疗肿瘤中的用途及相关的产品和方法 | |
| WO2021068196A1 (en) | Methods of using il-33 protein in treating cancers | |
| US20220249621A1 (en) | TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS | |
| Dianat-Moghadam et al. | Immunotherapies targeting tumor vasculature: challenges and opportunities | |
| KR20230093282A (ko) | 폐암에 대한 lag-3 길항제 요법 | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| EP3976193A1 (en) | Dosing of bispecific t cell engager | |
| US20240216554A1 (en) | Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer | |
| WO2020123477A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| EP3194451A1 (en) | Treatment of tumours using peptide-protein conjugates | |
| US20210130456A1 (en) | Single-chain variable fragment of met monoclonal antibody and methods of use in car t cell therapy | |
| JPWO2019173289A5 (OSRAM) |